Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 9 of 14.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2020-005448-48 Sponsor Protocol Number: CN42097 Start Date*: 2022-03-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUT...
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003126-83 Sponsor Protocol Number: EMR200559005 Start Date*: 2014-06-23
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekl...
    Medical condition: Relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000048-23 Sponsor Protocol Number: P2-IMU-838-PMS Start Date*: 2021-11-04
    Sponsor Name:Immunic AG
    Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
    Medical condition: Progressive forms of Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    26.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006333-27 Sponsor Protocol Number: 105MS301 Start Date*: 2009-06-19
    Sponsor Name:Biogen Idec LTD
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple ...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) DE (Completed) BE (Completed) NL (Completed) ES (Completed) CZ (Completed) BG (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006465-16 Sponsor Protocol Number: rhGH in MS Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001009-25 Sponsor Protocol Number: DR04-07-02 Start Date*: 2005-07-16
    Sponsor Name:DR DIMENSIONE RICERCA
    Full Title: Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA.
    Medical condition: Multiple sclerosis treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001337-17 Sponsor Protocol Number: msuspio1muc Start Date*: 2007-09-25
    Sponsor Name:Max-Planck-Institute of Psychiatry
    Full Title: Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multipl...
    Medical condition: Patients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028245 Multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007015-32 Sponsor Protocol Number: CENA713DDE18 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with mul...
    Medical condition: cognitive impairment in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002178-22 Sponsor Protocol Number: 11-AVR-130 Start Date*: 2011-12-26
    Sponsor Name:Avanir Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ...
    Medical condition: Central Neuropathic Pain in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002969-38 Sponsor Protocol Number: CFTY720DDE07 Start Date*: 2011-11-08
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingo...
    Medical condition: Fatigue in Patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013333-24 Sponsor Protocol Number: EMR 701048-525 Start Date*: 2009-08-03
    Sponsor Name:MERCK SERONO SPA
    Full Title: Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inje...
    Medical condition: RELAPSING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022066-28 Sponsor Protocol Number: CFTY720DDE01 Start Date*: 2011-01-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple ...
    Medical condition: relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000499-25 Sponsor Protocol Number: 28733 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Serono International S.A.
    Full Title: International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patien...
    Medical condition: Relapsing forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003147-19 Sponsor Protocol Number: BECRO/MINERALstudy Start Date*: 2016-07-18
    Sponsor Name:PALUPA Medical Ltd
    Full Title: Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Cont...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004602-97 Sponsor Protocol Number: VITADEM Start Date*: 2013-01-11
    Sponsor Name:Javier Olascoaga Urtaza
    Full Title: ?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial?
    Medical condition: RELAPSING-REMITING MULTIPLE SCLEROSIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010661-23 Sponsor Protocol Number: 2009-010661-23 Start Date*: 2009-07-30
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: subjects affected by secondary-progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029205 SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004412-11 Sponsor Protocol Number: CBX-001 Start Date*: 2015-01-16
    Sponsor Name:Canbex Therapeutics Ltd
    Full Title: A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects wi...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-000674-31 Sponsor Protocol Number: CFTY720DDE15TS Start Date*: 2012-08-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®
    Medical condition: RNFLT in Patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002637-11 Sponsor Protocol Number: CFTY720DDE19 Start Date*: 2012-10-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated pa...
    Medical condition: Treatment statisfaction in patients with relapsing remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004040-30 Sponsor Protocol Number: EOC.NSI.11.01 Start Date*: 2013-05-24
    Sponsor Name:Ospedale Regionale di Lugano
    Full Title: Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study
    Medical condition: relapse-remitting multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 00:00:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA